Cargando…

Advances in mRNA vaccines

mRNA vaccines have been increasingly recognized as a powerful vaccine platform since the FDA approval of two COVID-19 mRNA vaccines, which demonstrated outstanding prevention efficacy as well as great safety profile. Notably, nucleoside modification and lipid nanoparticle-facilitated delivery has gr...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Mengyun, Wang, Zining, Xie, Chunyuan, Xia, Xiaojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214710/
https://www.ncbi.nlm.nih.gov/pubmed/36064266
http://dx.doi.org/10.1016/bs.ircmb.2022.04.011
_version_ 1784731075559292928
author Li, Mengyun
Wang, Zining
Xie, Chunyuan
Xia, Xiaojun
author_facet Li, Mengyun
Wang, Zining
Xie, Chunyuan
Xia, Xiaojun
author_sort Li, Mengyun
collection PubMed
description mRNA vaccines have been increasingly recognized as a powerful vaccine platform since the FDA approval of two COVID-19 mRNA vaccines, which demonstrated outstanding prevention efficacy as well as great safety profile. Notably, nucleoside modification and lipid nanoparticle-facilitated delivery has greatly improved the immunogenicity, stability, and translation efficiency of mRNA molecule. Here we review the recent progress in mRNA vaccine development, including nucleoside modification, in vitro synthesis and product purification, and lipid nanoparticle vectors for in vivo delivery and efficient translation. We also briefly introduce the clinical application of mRNA vaccine in preventing infectious diseases and treating inflammatory diseases including cancer.
format Online
Article
Text
id pubmed-9214710
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-92147102022-06-22 Advances in mRNA vaccines Li, Mengyun Wang, Zining Xie, Chunyuan Xia, Xiaojun Int Rev Cell Mol Biol Article mRNA vaccines have been increasingly recognized as a powerful vaccine platform since the FDA approval of two COVID-19 mRNA vaccines, which demonstrated outstanding prevention efficacy as well as great safety profile. Notably, nucleoside modification and lipid nanoparticle-facilitated delivery has greatly improved the immunogenicity, stability, and translation efficiency of mRNA molecule. Here we review the recent progress in mRNA vaccine development, including nucleoside modification, in vitro synthesis and product purification, and lipid nanoparticle vectors for in vivo delivery and efficient translation. We also briefly introduce the clinical application of mRNA vaccine in preventing infectious diseases and treating inflammatory diseases including cancer. Elsevier Inc. 2022 2022-06-21 /pmc/articles/PMC9214710/ /pubmed/36064266 http://dx.doi.org/10.1016/bs.ircmb.2022.04.011 Text en Copyright © 2022 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Li, Mengyun
Wang, Zining
Xie, Chunyuan
Xia, Xiaojun
Advances in mRNA vaccines
title Advances in mRNA vaccines
title_full Advances in mRNA vaccines
title_fullStr Advances in mRNA vaccines
title_full_unstemmed Advances in mRNA vaccines
title_short Advances in mRNA vaccines
title_sort advances in mrna vaccines
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214710/
https://www.ncbi.nlm.nih.gov/pubmed/36064266
http://dx.doi.org/10.1016/bs.ircmb.2022.04.011
work_keys_str_mv AT limengyun advancesinmrnavaccines
AT wangzining advancesinmrnavaccines
AT xiechunyuan advancesinmrnavaccines
AT xiaxiaojun advancesinmrnavaccines